News from NORD

NORD Provides Update on Tax Cuts and Jobs Act


 

The Tax Cuts and Jobs Act passed by Congress and signed into law by President Trump includes a reduction of the Orphan Drug Tax Credit (ODTC), a repeal of the Affordable Care Act’s individual mandate, and a temporary bolstering of the Medical Expense Deduction. While NORD supports the temporary strengthening of the Medical Expense Deduction, it opposed the repeal of the individual mandate and the reduction of the ODTC. Thanks to the work of rare disease advocates joining NORD in support for the ODTC, the tax credit was not repealed entirely, as was initially suggested, but rather was cut in half. NORD is grateful for the support it received on this issue and will continue to work to preserve the important orphan drug incentives in 2018.

Recommended Reading

NORD Reopens Call for Abstracts for Research Grants
MDedge Dermatology
Poster Abstracts Due January 31 for European Conference on Rare Diseases and Orphan Products
MDedge Dermatology
Beta Version of ClinicalTrials.gov Website Available for Public Testing
MDedge Dermatology
NORD Welcomes Five New Member Organizations
MDedge Dermatology
Rituximab tackles relapse of severe, difficult-to-treat pemphigus
MDedge Dermatology
Join 7,000 Miles Campaign to Support Programs for Rare Disease Patients
MDedge Dermatology
January 12 Is Deadline for Rare Impact Awards Nominations
MDedge Dermatology
NORD Awards Five Research Grants
MDedge Dermatology
Visit NORD’s Website to Learn About Current or Future Research Funding Opportunities
MDedge Dermatology
NORD Launches Year-Long 35th Anniversary Observance
MDedge Dermatology